A Bitter Pill to Swallow: The Challenge of Medication Nonadherence in Systemic Lupus Erythematosus

Shivani Garg,Laura C. Plantinga

DOI: https://doi.org/10.3899/jrheum.2024-0654

2024-09-03

The Journal of Rheumatology

Abstract:Systemic lupus erythematosus (SLE) is the most common life-threatening autoimmune disease and a leading cause of mortality among young women of Black race and Hispanic ethnicity.1 Treatment of SLE is complex, requiring immune-altering medicines to reduce disease activity and prevent disease-related damage. The decision to commit to long-term treatment with immune-altering medicines is difficult, especially given that such medicines carry the risk, albeit low, of side effects, teratogenicity, and toxicity. In the face of such a difficult decision, which is compounded by individual barriers such as economic insecurities, social desirability, mistrust, or cognitive dysfunction (Figure 1), more than 50% of patients self-discontinue medicines within 9 months, and 33% do not refill medicines.2-4 This strikingly high medication nonadherence accelerates the risk of flares requiring hospitalization and drives early mortality in SLE.3,5-8 Figure 1. Conceptual model of factors influencing the decision to take medications as prescribed. Med: medication; SLE: systemic lupus erythematosus. Taking medications as prescribed is a behavior driven by many interrelated factors (Figure 1). Patients have noted that they frequently receive incomplete information about medications during their often-hurried SLE visits.9 They may resort to using the internet to learn about their medications, which often confirms their preexisting fears of toxicity, prompting self-discontinuation.9,10 Moreover, patient knowledge of the benefits of medications may be suboptimal. For example, in one study, more than 80% of patients with SLE reported that they did not know that hydroxychloroquine could improve survival and protect organs in SLE.10 Thus, dedicated provider-patient discussions on the benefits vs harms of SLE medicines could support a patient's decision to continue therapy. Such discussions often work but can be time-consuming and difficult to adopt in busy clinical practices and low-resource settings. To further complicate this issue, without objective methods ... Address correspondence to Dr. L.C. Plantinga, Pride Hall #4403, 2540 23rd Street, San Francisco, CA 94110, USA. Email: laura.plantinga{at}ucsf.edu.

rheumatology